Integration of Bioinformatics and Biotechnology: A Potential Insight into Antidiabetic Drug Discovery

Diabetes mellitus is a complex non-communicable metabolic disorder that can lead to serioushealth complications such as heart disease, kidney failure, blindness, and peripheral neuropathyif not treated early. Its global prevalence is rising, demanding safer and more effectivetherapeutic options. Medicinal plants have long served as sources of bioactive compoundsprecursor to effective drugs against some longstanding diseases. However, there is variabilityin the phytochemical composition of plant material collected from the natural environment,especially due to environmental factors, seasonal changes, and genetic variation, which oftenlimit research reproducibility. This review highlights integration of bioinformatics andbiotechnology may address these challenges and improve drug discovery efficiency.Bioinformatics tools, especially molecular docking and ADMET prediction, enable the easyand quick identification and evaluation of plant-derived compounds targeting key diabeticproteins like insulin receptors, Glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase -4 (DPP-4) inhibitors and Glucose-dependent insulinotropic polypeptide (GIP) . These computationalapproaches reduce time, cost, and experimental uncertainty while predicting drug-likeproperties prior to in vitro or in vivo validations. Complementarily, biotechnology techniquessuch as tissue culture ensure the consistent production of genetically stable, disease-free plantmaterials rich in secondary metabolites independent of seasonal or environmental variations.Analytical methods like HPLC, GC-MS, and NMR further aid in compound isolation andcharacterization for further research to validate the potency of the identified and isolatedcompounds. Integration of bioinformatics and biotechnology therefore bridges the traditionalmedicinal plant research and modern drug discovery, ensuring reproducibility, standardization,and biodiversity conservation for antidiabetic drug discovery